Biochemistry and molecular biology of the human CYP2C subfamily

Pharmacogenetics

Volumn 4, Issue 6, 1994, Pages 285-299

  Goldstein, Joyce A ^a   De Morais, Sonia M F ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 NAPHTHYLOXYLACTIC ACID; BARBITURIC ACID DERIVATIVE; CYCLOGUANIL; CYTOCHROME P450 ISOENZYME; DIAZEPAM; DICLOFENAC; DRONABINOL; DRUG METABOLITE; HEXOBARBITAL; IBUPROFEN; IMIPRAMINE; MEFENAMIC ACID; MEPHENYTOIN; NAPHTHOXYLACTIC ACID; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PHENYTOIN; PIROXICAM; PROGUANIL; PROPRANOLOL; SULFAPHENAZOLE; TENOXICAM; TIENILIC ACID; TOLBUTAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN;

ALLELE; CAUCASIAN; EXON; GENETIC DISORDER; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LIVER MICROSOME METABOLISM; MOLECULAR BIOLOGY; MOLECULAR CLONING; POPULATION RESEARCH; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; STEROID METABOLISM; XENOBIOTIC METABOLISM;

AMINO ACID SEQUENCE; BASE SEQUENCE; CLONING, MOLECULAR; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; HUMAN; IN VITRO; LIVER; MIXED FUNCTION OXYGENASES; MOLECULAR BIOLOGY; MOLECULAR SEQUENCE DATA; MULTIGENE FAMILY; MUTATION; POLYMORPHISM (GENETICS); RECOMBINANT PROTEINS; RNA SPLICING; SEQUENCE HOMOLOGY, AMINO ACID; SUBSTRATE SPECIFICITY;

EID: 0028590127     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199412000-00001     Document Type: Article

References (99)

1. Aoyama T, Nagata K, Yamazoe Y, Kato R, Matsunaga K, Gelboin HV, Gonzalez FJ. Cytochrome b5 potentiation of cytochrome P-4 50 catalytic activity demonstrated by a vaccinia virusmediate in situ reconstitution system. Proc Natl Acad Sci USA 1990: 87. 5425-5429.
2. Adedoyin A, Prakash C, O’Shea D, Blair IA, Wilkinson GR. Stereoselective disposition of hexobarbital and its metabolites: relationship to the S-mephenytoin polymorphism in Caucasian and Chinese subjects. Pharmacogenetics 1994: 4, 27-38.
3. Andersson T, Regârdh C-G, Lou Y-C, Zhang Y, Dahl M-L, Bertilsson L. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992: 2, 25-31.
4. Andersson T, Miners JO, Veronese ME, Tassaneeywakyl W, Tassaneeyakul W, Meyer UA, Birkett DJ. Identification of human liver cytochrome P450 isoforms mediated omeprazole metabolism. Br J Clin Pharmacol 1993: 36, 521-530.
5. Baumann P, Jonzier-Perez M, Kerb L, Küpfer A, Tingueley D, Schöpf, J. Amitriptyline pharmacokinetics and clinical response. II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. Int Clin Psychopharmacol 1986: 1. 102-112.
6. Beaune P, Dansette PM, Mansuy D, Kiffel L, Finck M, Amar C, Leroux JP, Homberg JC. Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc Natl Acad Sci USA 1987: 84, 551-555.
7. Beaune P, Flinois J-P, Kiffel L, Kremers P, Lerous J-P. Purification of a new cytochrome P-450 from human liver microsomes. Biochim Biophys Acta 1985: 840, 364-370.
8. Bertilsson L, Kalow W. Why are diazepam metabolism and polymorphic S-mephenytoin hydroxylation associated with each other in white and Korean populations but not in Chinese populations. Clin Pharmacol Ther 1993: 53, 608-610.
9. Bertilsson L, Henthorn TK, Sanz F, Tybring G, Säwe J, Villen T. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin but not debrisoquine hydroxylation phenotype. Clin Pharmacol Ther 1989: 45, 348-355.
10. Bornheim LM, Lasker JM, Raucy JL. Human hepatic microsomal metabolism of A'-tetrahydrocannabinol. Drug Metab Dispos 1992: 20, 241-246.
11. Brosen K, Skjelbo E, Flachs H. Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark. Br J Clin Pharmacol 1993: 36, 105-108.
12. Brian WR, Srivastava PK, Umbenhauer DR, Lloyd RS, Guengerich FP. Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae. Biochemistry 1989: 28, 4993-4999.
13. Chen L-S, Yasumori T, Yamazoe Y, Kato R. Hepatic microsomal tolbutamide hydroxylation in Japanese: in vitro evidence for rapid and slow metabolizers. Pharmacogenetics 1993: 3, 77-85.
14. Chen D, Lepar G, Kemper B. A transcriptional regulatory element common to a large family of hepatic cytochrome P450 genes is a functional binding site of the orphan receptor HNF-4. J Biol Chem 1994: 269. 5420-5427.
15. Chiba K, Saitoh A, Koyama F, Tani M, Hayashi M, Ishizaki T. The role of S-mephenytoin 4'-hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation. Br J Clin Pharmacol 1994: 37, 237-242.
16. le Morais SME, Schweikl H, Blaisdell J, Goldstein JA. Gene structure and upstream regulatory regions of human CYP2C9 and CYP2CI8. Biochem Biophys Res Commun 1993: 194, 194-201.
17. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura, K, Meyer UA, Goldstein JA. The major defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994a: 269, 15419-15422.
18. de Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol Pharmacol 1994b: in press.
19. de Waziers I, Cugnenc PH, Leroux J-P, Beaune PH. Cytochrome P450 isozymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 1990: 253, 387-393.
20. Dieter HH, Müller-Eberhard U, Johnson EF. Identification of rabbit microsomal cytochrome P-450 isozyme, form 1, as a hepatic progesterone 21-hydroxylase. Biochem Biophys Res Commun 1982: 105, 515.
21. Doecke CJ, Veronese ME, Pond SM, Miners JO, Birkett DJ, Sansom LN, McManus ME. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br j Clin Pharmacol 1991: 31, 124-130.
22. Funck-Brentano C, Bosco O, Jacqz-Aigrain E, Keundjian A, Jaillon P. Relation between chloroguanide bioactivation to cycloguanil and the genetically determined metabolism of mephenytoin in humans. Clin Pharmacol Ther 1992: 51, 507-512.
23. Furuya H, Meyer UA, Gelboin HV, Gonzalez FJ. Polymerase chain reaction-directed identification cloning and quantification of human CYP2C18 mRNA. Mol Pharmacol 1991: 40, 375-382.
24. Garcia MPL, Dansette PM, Valadon P, Amar C, Beaune P. Guengerich FP, Mansuy D. Human-liver cytochromes P-450 expressed in yeast as tools for reactive-metabolite formation studies. Oxidative activation of tienilic acid by cytochromes P-4502C9 and 2C10. Eur J Biochem 1993: 213, 223-232.
25. Ged C, Beaune, P. Isolation of the human cytochrome P-450 UC8 gene: multiple glucocorticoid responsive elements in the 5'-region. Biochim Biophys Acta 1991: 1088, 433-435.
26. Ged C, Beaune, P. Partial sequence and polymerase chain reactionmediated analysis of expression of the human CYP2C18 gene. Pharmacogenetics 1992: 2, 109-113.
27. Ged C, Umbenhauer DR, Bellew TM, Bork RW, Srivastava P, Shinriki N, Lloyd RS, Guengerich FP. Characterization of cDNAs, mRNAs, and proteins related to human liver microsomal cytochrome P-450 (S)-mephenytoin 4'-hydroxylase. Biochemistry 1988: 27, 6929-6940.
28. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Raucy JL, Kitareewan S, Lasker JM, Ghanayem B. Evidence for a role for 2C19 in metabolism of S-mephenytoin in humans. Biochemistry 1994: 33, 1743-1752.
29. Gram IT. Plasma level monitoring of tricyclic antidepressant therapy. Clin Pharmacokinet 1977: 2, 237-251.
30. Gut J, Meier UT, Catin T, Meyer UA. Mephenytoin-type polymorphism of drug oxidation: purification and characterization of a human liver cytochrome P-450 isozyme catalyzing microsomal mephenytoin hydroxylation. Biochem Biophys Acta 1986: 884, 435-447.
31. Heinemeyer G, Gramm HJ, Simgen W, Denhardt R, Roots I. Kinetics of hexobarbital and dipyrone in critical care patients receiving high-dose pentobarbital. Eur J Clin Pharmacol 1987: 32, 273-277.
32. Hermans JJR, Thijssen HHW. Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. Br I Pharmacol 1993: 100, 482-490.
33. Inaba T, Jurima M, Kalow, W. Family studies of mephenytoin hydroxylation deficiency. Am J Hum Genet 1986: 38, 768-772.
34. Inaba T. Phenytoin: Pharmacogenetic polymorphism of 4’-hydroxylation. Pharmacol Tiler 1990: 46, 341-347.
35. Jansson I, Tamburini PP, Favreau LV, Schenkman JB. The interaction of cytochrome b5 with four cytochrome P-450 enzymes from the untreated rat. Drug Metab Dispos 1985: 13, 453-458.
36. Jansson I, Kpstein PM, Bains S, Schenkman JB. Inverse relationship between cytochrome P-450 phosphorylation and complexation with cytochrome b5. Arch Biochem Biophgs 1987: 259. 441-448.
37. Kaminsky I.S, de Morais SMF, Faletto MB, Dunbar D, Goldstein JA. Correlation of human P4502C substrate specificities with primary structure-warfarin as a probe. Mol Pharmacol 1993: 43, 234-239.
38. Kimura S, Pastewka J, Gelboin HV, Gonzalez FJ. cDNA and amino acid sequences of two members of the human P450I1C gene subfamily. Nucleic Acids Res 1987: 15, 10053-10054.
39. Knodell RG, Hall SD, Wilkinson GR, Guengerich FP. Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. J Pharmacol Exp Titer 1987: 241, 1112-1119.
40. Knodell RG, Dubey RK, Wilkinson GR, Guengerich FP. Oxidative metabolism of hexobarbital in human liver: relationship to polymorphic S-mephenytoin 4'-hydroxylation. J Pharmacol Exp Ther 1988: 245, 845-849.
41. Küpfer A, Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 1984: 26, 753-759.
42. Küpfer A, Branch RA. Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation. Clin Pharmacol Ther 1985: 38. 414-418.
43. Kutt H, Wolk M, Scherman R, McDowell F. Insufficient parahydroxylation as the cause of diphenylhydantoin toxicity. Neurology 1964: 14, 542-548.
44. Leemann TD, Transon C, Bonnabry P, Dayer P. A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs. Drugs Exp Clin Res 1993a: 19, 189-195.
45. Leeman T, Transon C, Dayer P. Cytochrome P450TB (CYP2C): A major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver. Life Sci 1993b: 52. 29-34.
46. Leeman T, Bonnabry P, Dayer P. Stereoand nonstereoselective oxidation by P450TB (CYP2C): The major elimination pathway of ibuprofen. Presented at the American Society for Clinical Pharmacology and Therapeutics, 1994.
47. Lemoine A, Gautier JC, Azoulay D, Kiffel L, Belloc C, Guengerich FP, Maurel P, Beaune P, Leroux JP. Major pathway of imipramine metabolism is catalyzed by cytochromes P4501A2 and P-4503A4 in human liver. Mol Pharmacol 1993: 43, 827-832.
48. Leo MA, Lasker JM, Raucy JL, Kim C-I, Black M, Lieber CS. Metabolism of retinol and retinoic acid by human liver cytochrome P450IIC8. Arch Biochem Biophys 1989:269, 305-312.
49. Lindberg RLP, Negishi M. Alteration of mouse cytochrome P450coh substrate specificity by mutation of a single aminoacid residue. Nature 1989: 339, 632-634.
50. Meehan RR, Gosden JR, Rout D, Hastle ND, Friedberg T, Adesnik M, Buckland R, van Heyningen V, Fletcher J, Spurr NK, Sweeney J, Wolf CR. Human cytochrome P-440 PB-1: A multigene family involved in mephenytoin and steroid oxidations that maps to chromosome 10. Am J Hum Genet 1988: 42, 26-37.
51. Morel F, Beaune PH, Ratanasavanh D, Flinois J-P, Yang C-S, Guengerich FP, Guilliouzo A. Expression of cytochrome P-450 enzymes in cultured human hepatocytes. Eur J Biochem 1990: 191. 437-444.
52. Muller R, Schmidt WK, Stier A. The site of cyclic AMP-dependent protein kinase catalyzed phosphorylation of cytochrome P-450 LM2. FEBS Lett 1985: 187, 21-24.
53. Nakamura K, Goto F, Ray WA, McAllister GB, Jacqz K, Wilkinson GR. Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985: 38, 402-408.
54. Okino ST, Quattrochi LC. Pendurthi UR. McBride OW, Tukey RH. Characterization of multiple human cytochrome P-450 1 cDNA's. I Biol Chem 1987: 262, 16072-16079.
55. Page MA, Boutagy JS, Shenfield GM. A screening test for slow metabolizers of tolbutamide. Br J Clin Pharmacol 1991: 31, 649-654.
56. Relling MV, Aoyama T, Gonzalez FJ, Meyer UA. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J Pharmacol Exp Ther 1990: 252, 442-447.
57. Rettie AH, Korzekwa R, Kunze KL, Lawrence RF, Kddy AC, Aoyama T, Gelboin HV, Gonzalez FJ, Träger WF. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: A role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Client Res Toxicol 1992: 5. 54-59.
58. Rettie A, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994: 4, 39-42.
59. Romkes M, Faletto MB, Blaisdell JA, Raucy JL, Goldstein JA. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry 1991: 30, 3247-3255.
60. Ruckpaul K, Rein H, Black J. Frontiers in biotransformation, Vol. 1. London, New York, and Philadelphia, PA: Taylor & Francis, 1989: 1-65.
61. Scott J, Poffenbarger PL. Pharmacogenetics of tolbutamide metabolism in humans. Diabetes 1979: 28, 41-51.
62. Shaw G-C, Fulco A. Inhibition by barbiturates of the binding of the Bm3Rl repressor to its operator site on the barbiturate-inducible cytochrome P4 50BM3 gene of Bacillus megaterium. J Biol Client 1993: 268, 2997-3004.
63. Shimada T, Misono KS, Guengerich FP. Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism: purification and characterization of two similar forms involved in the reaction. J Biol Chem 1986: 261, 909-921.
64. Sindrup SH, Brosen K, Hansen MGJ, Aaes-Jorgensen T, Overo KF, Gram LF. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 1993: 13. 11-17.
65. Skjelbo R, Brosen K, Hallas J, Gram LF. The mephenytoin oxidation polymorphism is partially responsible for the Ndemethylation of imipramine. Clin Pharmacol Ther 1991: 49, 18-23.
66. Skjelbo E, Gram LF, Brosen K. The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R ratio). A population study. Br J Clin Pharmacol 1993: 35. 331-334.
67. Sladek FM, Zhong W, Lai E, Darnell JE Jr. Liver-enriched transcription factor HNF-4 is a novel member of the steroid hormone receptor superfamily. Genes Dev 1990: 4, 2353-2565.
68. Sohn D-R, Kobayashi K, Chiba K, Lee K-H, Shin S-G, Ishizaki T. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an oriental population. J Phtmtacol Exp Ther 1992a: 262, 1195-1202.
69. Sohn D-R, Kusaka M, Ishizaki T, Shin S-G, Jang I-J, Chiba K. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther 1992b: 52, 160-169.
70. Srivastava PK, Yun C-H, Beaune PH, Ged C, Guengerich FP. Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4'-hydroxylase cytochrome P-450 enzymes. Mol Pharmacol 1991: 40, 69-79.
71. Tamburini PP, White RH, Schenkman JB. Chemical characterization of protein-protein interactions between cytochrome P-450 and cytochrome b5. J Biol Client 1985: 260, 4007-4015.
72. Umbenhauer DR, Martin MV, Floyd RS, Guengerich FP. Cloning and sequence determination of a complementary DNA related to human liver microsomal cytochrome P-450 S-mephenytoin 4'-hydroxylase. Biochemistry 1987: 26, 1094-1099.
73. Vasko MR, Bell RD, Daly DD, Pippenger CE. Inheritance of phenytoin hypometabolism: a kinetic study of one family. Clin Pharmacol Ther 1980: 27, 96-103.
74. Venepally P, Chen D, Kemper B. Transcriptional regulatory elements for basal expression of cytochrome P450IIC genes. J Biol Client 1992: 267, 17333-17338.
75. Vermeij P, Ferrari MD, Buruma OJ, Veenema H, de Wolf FA. Inheritance of poor phenytoin parahydroxylation capacity in a Dutch family. Clin Pharmacol Ther 1988: 44. 588-593.
76. Veronese MK, Mackenzie PI, Doecke C, McManus ME, Miners JO, Birkett DJ. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem Biophys Res Commun 1991: 175, 1112-1118.
77. Veronese ME, Miners JO, Rees DTP, Birkett DJ. Tolbutamide hydroxylation in humans: lack of bimodality in 106 healthy subjects. Pharmacoyenetics 1993a: 3, 86-93.
78. Veronese ME, Doecke CJ. Mackenzie PI, McManus ME, Miners JO, Rees DTP, Gasser R, Meyer UA, Birkett DJ. Site directed mutation studies of human liver cytochrome P-4 50 isozymes in the CYP2C subfamily. Biochem J 1993b: 289, 533-538.
79. Wang P, Mason PS, Guengerich FP. Purification of human liver cytochrome P-450 and comparison to the enzyme isolated from rat liver. Arch Biochem Biophys 1980: 199. 206-219.
80. Wang PP, Beaune P, Kaminsky ES, Dannan GA, Kadlubar FF, Earrey D, Guengerich FP. Purification and characterization of six cytochrome P-450 isozymes from human liver microsomes. Biochemistry 1983: 22, 5375-5383.
81. Ward SA, Goto F. Nakamura K. Jacqz E, Wilkinson GR, Branch RA. S-Mephenytoin 4'-hydroxylase is inherited as an autosomal-recessive trait in Japanese families. Clin Pharmacol Ther 1987: 42, 96-99.
82. Ward SA, Walle T, Walle UK, Wilkinson GR, Branch RA. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther 1989a: 45, 72-79.
83. Ward SA, Watkins WM, Mberu E, Saunders JE, Koech DK, Gilles HM, Howells RF, Breckenridge AM. Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man. Br J Clin Pharmacol 1989b: 27, 781-787.
84. Ward SA, Helsby NA, Skjelbo E, Brosen K. Gram EF, Breckenridge AM. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism a panel study. Br J Clin Pharmacol 1991: 31, 639-692.
85. Waxman DJ, Eapenson DP, Aoyana T, Gelboin HV, Gonzalez FJ, Korzekwa K. Steroid hormone hydroxylase specificities of eleven cDNAexpressed human cytochrome P450s. Arch Biochem Biophys 1991: 290, 160-166.
86. Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA. Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 1984: 36, 773-780.
87. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 1989: 43, 53-76.
88. Wrighton SA, Thomas PE, Willis P, Maines SE, Watkins PB, Eevin W, Guzelian PS. Purification of a human liver cytochrome P-450 immunochemically related to several cytochromes P-450 purified from untreated rats. J Clin Invest 1987: 80, 1017.
89. Wrighton SA, Stevens JC, Becker GW, Van den Branden M. Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and S-mephenytoin 4'-hydroxylation. Arch Biochem Biophys 1993: 306, 240-245.
90. Yano M, Falvey E, Gonzalez FJ. Role of the liver-enriched transcription factor DBP in expression of the cytochrome P450 CYP2C6 gene. Mol Cell Biol 1992: 12, 2847-2854.
91. Yasumori TS, Kawano K, Nagata M, Shimada Y, Yamazoe Y, Kato R. Nucleotide sequence of a human liver cytochrome P-450 related to the rat male specific form. J Biochem (Tokyo) 1987: 102, 1075-1082.
92. Yasumori T, Murayama N, Yamazoe Y, Kato R. Polymorphism in hydroxylation of mephenytoin and hexobarbital stereoisomers in relation to hepatic P-450 human 2. Clin Pharmacol Ther 1990: 47, 313-322.
93. Yasumori T, Yamazoe Y, Kato R. Cytochrome P-450 human-2 (P-4501IC9) in mephenytoin hydroxylation polymorphism in human livers: differences in substrate and stereoselectivities among microheterogeneous P-450IIC species expressed in yeasts. J Biochem 1991: 109, 711-717.
94. Yasumori T, Nagata K, Yang SK, Chen E-S, Murayama N, Yamazoe Y, Kato R. Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate concentration dependent manner. Pharmacoyenetics 1993: 3, 291-301.
95. Yun C-H, Shimada T, Guengerich FP. Roles of human liver cytochrome P4502C and 3A enzymes in the 3-hydroxylation of benzo(a)pyrene. Cancer Res 1992: 52, 1868-1874.
96. Zhang Y, Reviriego J, Eou VQ, Sjöqvist F, Bertilsson L. Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: interethnic differences in comparison with white subjects. Clin Pharmacol Ther 1990: 48, 496-502.
97. Zhao J, Eeemann T, Dayer P. In vitro oxidation of oxicam NSAIDS by a human liver cytochrome P450. Life Sci 1992: 51, 575-581.
98. Zhou HE, Anthony EB, Wood AJ, Wilkinson GR. Induction of polymorphic 4'-hydroxylation of S-mephenytoin by rifampicin. Br J Clin Pharmacol 1990: 30, 471-475.
99. Zilly W, Breimer DD, Richter E. Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance. Eur J Clin Pharmacol 1975: 9, 219-227.